SPRB - Spruce Biosciences' Hormone Treatment Stumbles In Trials Prompts Stock Freefall | Benzinga
Spruce Biosciences Inc (NASDAQ:SPRB) shares plummeted on Thursday after the company released topline results from its CAHmelia-203 Phase 2b study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH.
The CAHmelia-203 study did not achieve the primary efficacy endpoint of the assessment of dose response for the change in A4 from baseline to week 12.
The preliminary pharmacokinetic analysis of the CAHptain-205 study suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.
HC Wainwright notes that despite considering tildacerfont an active drug, the setback in the CAHmelia-203 trial has created uncertainty about its future development and regulatory submission timeline.
Consequently, they are downgrading their ...